Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) stock observed trading -28.54% off 52-week high price. On the other end, the stock has been noted 32.16% away from low price over the last 52-weeks. The stock disclosed a move of -10.41% away from 50 day moving average and -2.44% away from 200 day moving average. Moving closer, we can see that shares have been trading -10.28% off 20-day moving average. It has market cap of $2.52B.
On Jan. 31, 2020, Biohaven Pharmaceutical Holding Company Ltd. (NYSE:BHVN) declared the appointment of Michael Heffernan to its Board of Directors (Board).
Mr. Heffernan is a seasoned biopharmaceutical leader with over 25 years of commercial experience. Mr. Heffernan is a pharmacist and began his career at Eli Lilly and Company where he served in numerous sales and marketing roles. Mr. Heffernan most recently served as Founder and CEO of Collegium (Nasdaq: COLL), and remains Chairman of its Board of Directors. Mr. Heffernan has been an advisor, investor and board member in a number of biopharmaceutical and healthcare services companies. His recent board memberships include: TyRx (sold to Medtronic), PreCision Dermatology (sold to Valeant), Ocata Therapeutics (sold to Astellas), and Veloxis (Sold to Asahi Kasei). He is also currently Chairman of the Board of Carisma Therapeutics and of Indalo Therapeutics and is a member of the board of Akebia Therapeutics (AKBA) and Trevi Therapeutics (TRVI).
Vlad Coric, M.D., CEO of Biohaven, commented, As we prepare for commercialization of our lead asset, we are excited to welcome Mike as a key member of our Board effective January 31, 2020. Mike is an experienced commercial leader and entrepreneur who started and built his own company through commercialization. He has cross-functional executive experience in commercial operations, global sales and marketing, clinical development, regulatory affairs, and business development within the biopharmaceutical industry. Mike will be a tremendous asset to us in this first year of our anticipated commercial launch.
he stock was observed in the 5 days activity at -11.03%. The one month performance of stock was -10.93%. BHVN’s shares are at 7.21% for the quarter and driving a 27.30% return over the course of the past year and is now at -10.93% since this point in 2018. The average volatility for the week and month was at 4.98% and 5.49% respectively. There are 52.03M shares outstanding and 43.35M shares are floated in market.